Aripiprazole in the acute and maintenance phase of bipolar I disorder

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 1-6

  Zupancic, Melanie ^a   Gonzalez, Misty L ^a,b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

Acute treatment; Aripiprazole; Bipolar disorder; Maintenance treatment

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; OLANZAPINE; PLACEBO; QUINIDINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; VALPROATE SEMISODIUM; VALPROIC ACID;

ADJUVANT THERAPY; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DOPAMINE RECEPTOR BLOCKING; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; HUMAN; HYPOMANIA; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MENTAL INSTABILITY; METABOLIC SYNDROME X; MIXED MANIA AND DEPRESSION; MONOTHERAPY; ONSET AGE; RECURRENCE RISK; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84857078860     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S22579     Document Type: Article

References (40)

1. Sajatovic M. Bipolar disorder: disease burden. American J Manag Care. 2005;11(Suppl 3):S80-S84.
2. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161-174.
3. Goldberg JF, Harrow M. Consistency of remission and outcome in bipolar nad unipolar mood disorders: a 10 year prospective follow up. J Affect Disord. 2004;81(2):123-131.
4. Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord. 2002; 71(1-3):131-139.
5. Williams M, Shah ND, Wagie A, Wood D, Frye M. Direct costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysis. Psychiatr Serv. 2011;62(9):1073-1078.
6. Kessler RC, McGonagle KA, Zhao S, et al. Lifetme and 12-month prevalence of DSM-III-R psychiatric disorders in the Unites States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.
7. Angst J, Gamma A, Lewinsohn P. The evolving epidemiology of bipolar disorder. World Psychiatry. 2002;1(3):146-148.
8. Angst J, Cui L, Swendsen J, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010;167(10):1194-1201.
9. Zimmermann P, Brückl T, Nocon A, et al. Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry. 2009;66(12):1341-1352.
10. Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry. 2011; 168(1):40-48.
11. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276(4):293-299.
12. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994;31(4):281-294.
13. Hendrick V, Altshuler LL, Gitlin MJ, Delrahim S, Hammen C. Gender and bipolar illness. J Clin Psychiatry. 2000;61(5):393-396.
14. Bebbington P, Ramana R. The epidemiology of bipolar affective disorder. Soc Psychiatry Psychiatr Epidemiol. 1995;30(6): 279-292.
15. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area study. JAMA. 1990;264(19):2511-2518.
16. Chen YW, Dilsaver SC. Comorbidity of panic disorder in bipolar illness: evidence from the Epidemiologic Catchment Area Survey. Am J Psychiatry. 1995;152(2):280-282.
17. Chen YW, Dilsaver SC. Comorbidity for obsessive compulsive disorder in bipolar and unipolar disorders. Psychiatry Res. 1995;59(1-2): 57-64.
18. Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH. Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. J Clin Psychiatry. 2008;69(11):1751-1757.
19. Stewart C, El-Mallakh RS. Is bipolar disorder overdiagnosed among patients with substance abuse? Bipolar Disord. 2007;9(6):646-648.
20. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord. 1999;52(1-3):135-144.
21. Dunner DL. Clinical consequences of under-recognized bipolar spectrum disorder. Bipolar Disord. 2003;5(6):456-463.
22. Kupfer D, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 2002;63(2):120-125.
23. Dalton EJ, Cate-Carter TD, Mundo E, Parikh SV, Kennedy JL. Sucide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord. 2003;5(1):58-61.
24. Muzina D, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry. 2005; 39(8):652-661.
25. Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry. 2002;10(2):59-75.
26. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217-222.
27. Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry. 2007;7:40.
28. Bristol-Myers and Squibb. Abilify Prescribing Information.
29. SM, editor. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press; 2008.
30. Challenges and solutions in developing new medications for schizophrenia. J Clin Psychiatry. 2010;71(10):1391-1399.
31. McIntyre R, Yoon J, Jerrell JM, Liauw SS. Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. Neuropsychiatr Dis Treat. 2011;7:319-323.
32. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187:235-242.
33. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20(4):536-546.
34. Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo controlled study. Am J Psychiatry. 2008;165:1316-1325.
35. Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009;112(1-3): 36-49.
36. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2009;194(1):40-48.
37. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160(9): 1651-1658.
38. Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100 week double blind study versus placebo. J Clin Psychiatry. 2007;68(10):1480-1491.
39. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46 week, open label extension following a 6 week double blind study. Curr Med Res Opin. 2010;26(6):1485-1496.
40. Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 2011;13(2):133-144.